From: Clinical implications of serum thrombomodulin in PR3-ANCA-associated vasculitis
n | Generalized WG | Limited WG | Control | P | |
---|---|---|---|---|---|
sTM (ng/ml) | 40 | 108 ± 12 | 56 ± 2 | 12 ± 4 | 0.0015 |
ESR (mm/h) | 40 | 79.1 ± 26.6 | 27.3 ± 10.7 | 8.4 ± 4.2 | 0.01 |
CRP (mg/dl) | 40 | 13.7 ± 7.8 | 1.5 ± 0.98 | 1.5 ± 0.98 | 0.1 |
Fibrinogen (mg/dl) | 40 | 426.5 ± 164.2 | 212.6 ± 21.6 | 160.6 ± 22.6 | 0.04 |
Leucocytes/μl | 40 | 9900 ± 3500 | 5400 ± 1500 | 4400 ± 1500 | 0.008 |
Thrombocytes/μl | 40 | 398.7 ± 134.1 | 223.4 ± 57.5 | 130.4 ± 59.5 | 0.0021 |
Hg (g/%) | 40 | 11.4 ± 2.4 | 12.2 ± 1.8 | 13.2 ± 1.8 | 0.004 |
GFR (ml/min) | 40 | 64.21 ± 16.8 | 76.8 ± 9.4 | 96.8 ± 8.4 | 0.005 |
c-ANCA | 14 | 640 ± 160 | 80 ± 40 | 0 | 0.24 |
p-ANCA | 3 | 160 ± 80 | 80 ± 20 | 0 | 0.19 |
PR3-ANCA | 16 | 100 ± 80 | 8.2 ± 4.6 | 0 | 0.001 |
MPO-ANCA | 2 | 40 ± 14 | 9.4 ± 2.1 | 0 | 0.28 |
DEI | 25 | 12 (8-14) | 6 (3-9) | 0 | 0.004 |
BVAS-WG | 25 | 21 (16-32) | 14 (12-16) | 0 | 0.0001 |